Please login to the form below

Not currently logged in
Email:
Password:

XenoPort appoints chief medical officer

Richard Kim led Tysabri programme at Biogen Idec

XenoPort has appointed Dr Richard Kim as chief medical officer and senior VP, clinical development and medical affairs.

Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome and postherpetic neuralgia.

He joined XenoPort from Biogen Idec where he was joint programme team leader for the hugely successful multiple sclerosis (MS) treatment Tysabri (natalizumab) helping with drug's launches in markets that included the US.

Prior to joining Biogen Idec Dr Kim was with Merck Serono, serving as medical director for the phase III programme of cladribine, which failed to impress in MS.

XenoPort will look to Dr Kim's experience as it prepares to advance its drug candidate XP23829, which is being studied as a treatment for psoriasis and/or relapsing forms of MS, into phase II development.

6th February 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

How ‘Greenwashing’ accusations could delay the very changes its supporters demand
Are shouts of companies ‘greenwashing’ to provide a façade of environmental and ethical respectability causing more harm than good? Or should we call out practices that we believe are papering...
What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...